| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11060-011-0713-3 |
| P698 | PubMed publication ID | 21971734 |
| P50 | author | Sara Booth | Q38589481 |
| Richella Ryan | Q39182578 | ||
| Stephen J. Price | Q43284455 | ||
| P2860 | cites work | Corticosteroids for acute ischaemic stroke | Q24234485 |
| Tight junctions of the blood-brain barrier: development, composition and regulation | Q24292730 | ||
| Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor | Q24561970 | ||
| Brain endothelial cell-cell junctions: how to "open" the blood brain barrier | Q24654117 | ||
| Occludin expression in microvessels of neoplastic and non-neoplastic human brain | Q28202259 | ||
| Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study | Q30427266 | ||
| Genesis of the use of corticosteroids in the treatment and prevention of brain edema | Q33336988 | ||
| Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma | Q33382596 | ||
| Corticosteroid-induced osteoporosis: pathogenesis and prevention | Q34008197 | ||
| Peptic ulcer disease and other complications in patients receiving dexamethasone palliation for brain metastasis | Q34112442 | ||
| VEGF in brain tumors | Q34178821 | ||
| Corticosteroid-Induced osteoporosis: detection and management | Q34323719 | ||
| Systemic corticosteroid therapy--side effects and their management | Q34478085 | ||
| A prospective survey of the use of dexamethasone on a palliative care unit. | Q34513662 | ||
| A retrospective observation of corticosteroid use at the end of life in a hospice | Q35012391 | ||
| Aquaporin-4 expression is increased in oedematous human brain tumours. | Q35465645 | ||
| The eicosanoid cascade: possible role in gliomas and meningiomas | Q35615457 | ||
| Studies on cerebral edema; reaction of the brain to air exposure; pathologic changes | Q51374356 | ||
| Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. | Q55475091 | ||
| Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. | Q55475234 | ||
| Corticosteroid toxicity in neuro-oncology patients | Q69426282 | ||
| Acute adverse reactions to prednisone in relation to dosage | Q70438563 | ||
| Management of pituitary-adrenal suppression secondary to corticosteroid therapy | Q70806532 | ||
| Complications of corticosteroid therapy | Q72174881 | ||
| Quantitation of peritumoural oedema and the effect of steroids using NMR-relaxation time imaging and blood-brain barrier analysis | Q72847134 | ||
| Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study | Q73402388 | ||
| The prescription of steroids in the terminal phase | Q78437648 | ||
| Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery | Q78844001 | ||
| Withdrawal acute psychosis after corticosteroid discontinuation | Q80446211 | ||
| Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition | Q35641884 | ||
| Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases. | Q35876272 | ||
| The management of brain edema in brain tumors | Q35997245 | ||
| Corticosteroids in terminal cancer--a prospective analysis of current practice | Q36705000 | ||
| Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. | Q36748193 | ||
| Clinical neurosciences in the decade of the brain: hypotheses in neuro-oncology. VEG/PF acts upon the actin cytoskeleton and is inhibited by dexamethasone: relevance to tumor angiogenesis and vasogenic edema. | Q36987703 | ||
| The use and toxicity of steroids in the management of patients with brain metastases. | Q37078927 | ||
| Strategies for minimizing corticosteroid toxicity: a review | Q37331307 | ||
| The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. | Q37446357 | ||
| FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme | Q37629395 | ||
| The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline | Q37643538 | ||
| Glucocorticoid-induced myopathy | Q37753145 | ||
| Role of bevacizumab therapy in the management of glioblastoma. | Q37824254 | ||
| Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? | Q39406644 | ||
| Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier | Q39981254 | ||
| An overview of the adverse reactions to adrenal corticosteroids | Q41439848 | ||
| Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases | Q42090381 | ||
| Dexamethasone treatment of brain tumor patients: effects on regional cerebral blood flow, blood volume, and oxygen utilization | Q42229503 | ||
| Steroid myopathy in cancer patients. | Q42549536 | ||
| Neovasculature induced by vascular endothelial growth factor is fenestrated. | Q42650791 | ||
| Steroid requirements during radiotherapy for malignant gliomas | Q43148724 | ||
| Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas | Q44281661 | ||
| Capillary permeability factor secreted by malignant brain tumor. Role in peritumoral brain edema and possible mechanism for anti-edema effect of glucocorticoids | Q44318104 | ||
| Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index | Q44655350 | ||
| Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans | Q44760244 | ||
| Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
| Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial | Q46543487 | ||
| Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone | Q48173615 | ||
| Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors | Q48237868 | ||
| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group | Q48271471 | ||
| Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: a xenon-enhanced computed tomographic study | Q48415926 | ||
| Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals | Q48562103 | ||
| A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. | Q50913118 | ||
| Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. | Q51045428 | ||
| Use of dexamethasone in treatment of cerebral edema associated with brain tumors. | Q51304115 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 449-459 | |
| P577 | publication date | 2011-10-05 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Corticosteroid-use in primary and secondary brain tumour patients: a review | |
| P478 | volume | 106 |
| Q91030505 | A Reduced Exogenous Steroid Taper for Postoperative Brain Tumor Patients-A Case-Control Study |
| Q38779273 | Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report. |
| Q38187575 | End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review |
| Q92191362 | Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know? |
| Q28081953 | Gliomas and the vascular fragility of the blood brain barrier |
| Q38542829 | Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors |
| Q26992174 | Medical management of brain tumors and the sequelae of treatment |
| Q38042263 | Neurocognitive function after radiotherapy for paediatric brain tumours |
| Q89566621 | Provider views on perioperative steroid use for patients with newly diagnosed pediatric brain tumors |
| Q36440328 | Radiosurgical third ventriculostomy: Technical note |
| Q47984166 | Results of a Policy of Fast Tapering of Steroids After Resection Surgery in Glioblastoma |
| Q37382256 | Stereotactic radiosurgery boost to the resection cavity for cerebral metastases: Report of overall survival, complications, and corticosteroid protocol |
| Q44233551 | Steroid management in newly diagnosed glioblastoma. |
| Q35815301 | The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic |
| Q38154959 | Tumor-associated edema in brain cancer patients: pathogenesis and management |
| Q41464679 | Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire -Chronic for the evaluation of longer-term corticosteroid toxicity |
| Q34548198 | Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor |
Search more.